We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New, Easy-To-Use CRISPR-Based HIV Test Kit to Deliver Results in Minutes

By LabMedica International staff writers
Posted on 11 Jul 2024
Print article
Image: The prototype HIV tester can potentially test and detect results in just minutes (Photo courtesy of University of Florida)
Image: The prototype HIV tester can potentially test and detect results in just minutes (Photo courtesy of University of Florida)

With 1.3 million new HIV cases and 630,000 HIV-related deaths reported in 2022 by the World Health Organization, improving and simplifying HIV detection in patients is crucial for reducing outbreaks and the resultant deaths. Although home testing kits for various health conditions have gained popularity, advancements in HIV testing have been slower to develop. Traditional HIV tests typically only become effective several weeks post-infection, raising the risk of unintentional virus transmission. Now, an innovative HIV-detection test kit utilizing advanced CRISPR technology is under development and could act as an early-warning system, potentially saving millions of lives.

CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, represents a breakthrough in genetic engineering, allowing selective modifications to the DNA of organisms in lab environments. This technology leverages genome editing systems that occur naturally in bacteria. A research team at the University of Florida (Gainesville, FL, USA) is nearing completion of their HIV detection method that employs CRISPR technology. Promising rapid results, this test could enable earlier treatment for patients, potentially reducing viral loads to undetectable levels.

The innovative CRISPR-based kit is designed to measure HIV RNA levels quickly using a compact microfluidic device. This palm-sized prototype facilitates rapid self-testing soon after potential exposure, delivering results within minutes. With additional development, this self-testing kit could be available for use in various settings, including homes, doctor's offices, community clinics, and outreach locations like homeless shelters, within the next five years. The team's initial research into this HIV testing method has yielded encouraging results.

“Our goal is to develop a test kit that is not only highly advanced but also user-friendly, like a reliable alarm that detects potential issues before they escalate,” said Piyush Jain, Ph.D., an assistant professor at UF’s Department of Chemical Engineering, who is leading the research team. “This research is crucial given the staggering global impact of HIV and the critical need for early detection.” 

Related Links:
University of Florida

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Multichannel Pipette
CAPPSolo

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.